Stock SWTX SPRINGWORKS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Real-time Estimate Cboe BZX
Other stock markets
 12:47:47 2024-04-25 pm EDT 		5-day change 1st Jan Change
44.29 USD +2.10% Intraday chart for SpringWorks Therapeutics, Inc. +4.52% +21.62%
Mar. 12 Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
Mar. 06 JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
GL
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating
MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating
MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment
MT
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
GL
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
CI
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
GL
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
AQ
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows
MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
SpringWorks Therapeutics: Q4 Earnings Snapshot
AQ
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M
MT
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
GL
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating
MT
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
GL
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating
MT
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing
MT
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SWTX Stock
  4. News SpringWorks Therapeutics, Inc.